<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Dendritic cells (DCs) and regulatory T cells (Treg) play a major role in anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immune response of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the effect of radiochemotherapy on patients' blood immune cells and their predictive value for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: DCs and Treg of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) or <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (BC) patients were examined through multicolor flow cytometry before the beginning and after the first week of radiochemotherapy (RCT) </plain></SENT>
<SENT sid="3" pm="."><plain>DCs were stained for BDCA1 and BDCA2, Treg were stained for CD4, CD25, CD127 and FoxP3 </plain></SENT>
<SENT sid="4" pm="."><plain>IL-2, IL-10 and TNF-Î± plasma levels of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients were also determined </plain></SENT>
<SENT sid="5" pm="."><plain>We examined the interrelationship between immune cell count alterations, applied dose values, cytokine plasma levels as well as histopathological parameters </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: DCs were increased in BC and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients compared to healthy control individuals (HC) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients had higher levels of Treg (59.0%) compared to BC patients (31.3%) and HC (27.0%) </plain></SENT>
<SENT sid="8" pm="."><plain>Treg of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (58.7% vs. 41.3% p&lt;0.001) but not BC patients (31.3% vs. 38.8%, p=0.164) decreased distinctly after the first week of radiation therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Applied dose values and decrease of Treg correlated positively (r=0.216, p=0.054) </plain></SENT>
<SENT sid="10" pm="."><plain>We also found a positive correlation of IL-10 plasma levels and Treg levels (r=0.748, p=0.021) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with favorable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage (&lt;ypT3a) have higher levels of Treg after 5 days of RCT (49.4% vs. 34.0%, p=0.043) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Higher Treg levels are associated with favorable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage </plain></SENT>
<SENT sid="13" pm="."><plain>We hypothesize that a dramatic decrease of Treg after in vivo irradiation may be a good indicator for necessary dose adjustments in radiation therapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>